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HMGI-C belongs to the high-mobility-group-protein (HMG) family of architectural transcription factors and considerable interest has
recently been shown in its expression in neoplastic tissues and apparent involvement in tumorigenesis. We could previously
demonstrate an expression of HMGI-C mRNA in the peripheral blood of breast cancer patients for the first time. In this prospective
study, we evaluated the independent prognostic power of HMGI-C mRNA expression in the peripheral blood of an unselected
cohort of 69 patients with metastatic breast cancer using a hemi-nested reverse transcriptase polymerase chain reaction (RT–PCR)
followed by sequence analysis of the resulting PCR products. Multivariate analysis was performed using the Cox regression model.
HMGI-C mRNA was detected in peripheral blood from 21 out of 69 (30%) patients with metastatic breast cancer. Median survival
was 15.9 months in patients expressing HMGI-C, while in the group of patients without HMGI-C expression the median survival had
not been reached yet after a median follow-up of 24.7 months and 85.4% were still alive in this group. Disease-specific survival was
significantly worse for patients positive for HMGI-C in comparison to those not expressing HMGI-C (P¼0.0001). In a multivariate
regression analysis, HMGI-C remained an independent prognostic factor for overall survival (P¼0.001) besides oestrogen receptor
status (P¼0.024) and presence of metastases in liver and lungs (P¼0.029). HMGI-C expression in the peripheral blood of patients
with metastatic breast cancer is a powerful independent indicator for poor overall survival and this is the first study to demonstrate its
prognostic relevance in univariate and multivariate analysis.
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Breast cancer is the most common malignancy affecting women.
One area of intense breast cancer research has been in assessing
prognostic factors of patient outcomes, and several molecular
markers have been evaluated in association with established
histologic and clinical prognostic parameters of breast cancer
(Honkoop et al, 1998; Rizzieri et al, 1999; Sabbatini et al, 2000;
Silva et al, 2001).
Considerable interest in HMGI proteins, a subfamily of the high-
mobility-group-proteins, has been stimulated by observations that
they are involved in the fundamental biological processes of cell
proliferation and differentiation (Zhou and Chada, 1998). They
serve as transcription factors and take part in the regulation of
chromatin structure and function. HMGI proteins contain DNA
binding domains and are involved in the assembly of the correct
three-dimensional configuration of protein–DNA complexes
(Tallini and Dal Cin, 1999). The HMGI family comprises three
proteins: HMGI and HMGI(Y), which result from differential
splicing from a single gene, and HMGI-C, which is encoded by a
different gene, but shares some structural homologies with the
former two (Bustin and Reeves, 1996; Goodwin, 1998; Chau et al,
1999; Tallini and Dal Cin, 1999). HMGI proteins facilitate gene
activation through enhanceosome formation on inducible genes
during embryonal development and within rapidly dividing cells.
The family member HMGI-C was also shown to enhance the
activity of the transcription factor NF-kB (Mantovani et al, 1998).
The HMGI-C gene is normally almost exclusively expressed during
embryonic development and in haematopoietic stem cells in adults
(Rogalla et al, 1996). Experiments with knockout mice having both
HMGI-C alleles disrupted led to a pygmy phenotype in these mice
(Zhou et al, 1995).
An expression of antisense HMGI-C RNA was shown to prevent
retrovirally induced neoplastic transformation in rat thyroid cells
by Berlingieri et al (1995). These findings and studies on HMGI-C
expression in a variety of tumours (Chiappetta et al, 1995;
Kazmierczak et al, 1996, 1998; Staats et al, 1996; Rogalla et al, 1997,
1998; Rommel et al, 1997; Giannini et al, 1999; Klotzbucher et al,
1999) have substantiated the important role of HMGI-C in the
control of cell growth, differentiation and tumorigenesis. It could
also be detected in the peripheral blood of patients with leukaemia,
but no HMGI-C expression could be found in the peripheral blood
samples of healthy donors (Rommel et al, 1997; Sezer et al, 2000).
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yWe could recently demonstrate for the first time that HMGI-C is
expressed in the peripheral blood of breast cancer patients and
that this expression is restricted to patients with metastatic disease
(Sezer et al, 2000).
The purpose of the present study was to analyse the correlation
between HMGI-C expression in the peripheral blood of metastatic
breast cancer patients and clinicopathologic characteristics and
this is the first study to evaluate the prognostic relevance of HMGI-
C expression for survival using univariate and multivariate
analysis.
MATERIALS AND METHODS
Peripheral blood samples from an unselected cohort of 69 patients
with metastatic breast cancer prior to the initiation of a
chemotherapy were analysed in the present study. Institutional
ethical approval was obtained and informed consent was given by
the patients and healthy donors. Blood samples (5ml) were
immediately stabilised with DNA/RNA stabilisation reagent
(Roche Diagnostics, formerly Boehringer Mannheim, Germany)
after being drawn from the patient and processed according to the
manufacturer’s instructions.
Reverse transcription–polymerase chain reaction for
assessing the expression of HMGI-C mRNA
Briefly, mRNA was obtained using an mRNA kit (mRNA Isolation
Kit, Roche Diagnostics, formerly Boehringer Mannheim, Ger-
many), cDNA was synthesised using the adapter primer (AP2) and
Superscript II reverse transcriptase (RT) (Life Technologies,
Eggenstein, Germany) and HMGI-C expression was determined
using a hemi-nested reverse transcription–polymerase chain
reaction (RT–PCR), as previously described (Rogalla et al, 1996;
Sezer et al, 2000) and confirmed by DNA sequencing (ABI Prism
DNA sequencer, Perkin-Elmer).
Statistical analysis
All statistical analyses were performed using SPSS software
(Version 10.0, SPSS Inc, Chicago, IL, USA). Possible differences
in clinicopathologic characteristics of the patient groups with and
without circulating HMGI-C mRNA were analysed using exact w
2-
and Mann–Whitney tests. The Kaplan–Meier method was used to
estimate survival rates and log-rank tests were applied to compare
survival curves between two groups. Cox multivariate regression
analysis was used to assess the prognostic significances of the
Table 1 Association of HMGI-C expression with clinicopathologic characteristics of patients
HMGI-C expression
Variables Positive (%) Negative (%) P-value
a
Age (years)
Mean7s.d. 55.677.8 56.0713.1 0.80
Range 39.9 71.9 32.1 85.1
Median 55.3 58.4
Time from diagnosis to first metastatic event (months)
Mean7s.d. 27.1719.8 31.0731.0 0.87
Range 0.0 85.0 0.0 120.0
Median 23.0 25.5
Menopausal status 0.18
Premenopausal 0 (0) 5 (10.4)
Postmenopausal 19 (90.5) 38 (79.2)
Unknown 2 (9.5) 5 (10.4)
Histology 1.00
Ductal carcinoma 20 (95.2) 45 (93.8)
Lobular carcinoma 1 (4.8) 3 (6.2)
Oestrogen-receptor status 0.78
Positive 11 (52.4) 27 (56.2)
Negative 8 (38.1) 16 (33.3)
Unknown 2 (9.5) 5 (10.4)
Progesterone-receptor status 0.79
Positive 8 (38.1) 19 (39.6)
Negative 12 (57.1) 24 (50.0)
Unknown 1 (4.8) 5 (10.6)
Site of metastases
Any visceral 19 (90.5) 39 (81.3) 0.48
Lung 12 (57.1) 25 (52.1) 0.80
Liver 12 (57.1) 20 (41.7) 0.29
Lung and Liver 5 (23.8) 8 (16.7) 0.52
Bone 14 (66.7) 21 (42.6) 0.12
Soft tissues 5 (23.8) 13 (27.1) 1.00
Chemotherapy
Ever 16 (76.2) 29 (60.4) 0.28
Adjuvant 12 (57.1) 20 (41.7) 0.30
Previous palliative 7 (33.3) 10 (20.8) 0.36
Anthracyclines 9 (42.9) 19 (39.6) 1.00
Taxanes 7 (33.3) 10 (20.8) 0.37
Endocrine therapy 12 (57.1) 29 (60.4) 1.00
Tamoxifen 11 (52.4) 26 (54.2) 1.00
Letrozole 3 (14.3) 13 (27.1) 0.36
Radiation therapy 12 (57.1) 22 (45.8) 0.44
aP-values for age and time from diagnosis to the first metastatic event were obtained using the Mann–Whitney test; other
P-values were derived using the w
2-test.
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yvarious factors for overall survival, with variables entering the
model if changes in minus twice the log likelihood were
statistically significant at the 5% significance level. Proportional
hazard was tested with the log minus log plot.
Results
Expression of HMGI-C mRNA in the peripheral blood was detected
in 21 (30.4%) of the 69 patients with metastatic breast cancer.
Patient characteristics according to HMGI-C expression status are
listed in Table 1. There was no statistically significant difference
between the group of patients positive for HMGI-C expression and
the group of patients without detectable HMGI-C in terms of age,
time from diagnosis to first metastatic event, menopausal status,
histologic type, hormone receptor status and sites of metastases.
The two groups did not differ with respect to having ever received
chemotherapy, having received adjuvant or palliative chemother-
apy, treatment with taxanes or anthracyclines, endocrine therapy
or radiation therapy. Median length of follow-up was 24.7 months
for all patients. Median survival was 15.9 months in patients
expressing HMGI-C, 38% were still alive at the last follow-up
contact, while in the group of patients without HMGI-C expression
the median survival had not been reached yet, and 85.4% were still
alive at last follow-up contact (P¼0.0001). Kaplan–Meier analysis
showed that patients with HMGI-C expression had statistically
significant worse overall survival (P¼0.0001) (Figure 1). Cox
multivariate regression analysis performed after univariate ana-
lyses identified HMGI-C to be an independent poor prognostic
factor for patient survival (P¼0.001). In addition, positive
oestrogen receptor status was significant for better overall survival
(P¼0.024) and presence of metastases in both liver and lung was
significant for worse outcome (P¼0.029) (Tables 2 and 3).
DISCUSSION
HMGI-C is an architectural transcription factor and plays a key
role in important cellular processes such as DNA transcription in
rapidly dividing embryonal cells and in neoplastic cells (Tallini
and Dal Cin, 1999). It was found to be expressed in a variety of
tumour tissues, but not in normal tissue adjacent to the tumour
(Rogalla et al, 1996). In tumour tissues, a correlation between
HMGI-C expression and grading has been reported, and in a study
on HMGI-C expression in breast cancer tissues, HMGI-C was
predominantly noted in tumours with high histological grade
(Rogalla et al, 1997). Berlingieri et al (1995) demonstrated the
appearance of a highly malignant phenotype in relation with
HMGI-C expression in differentiated rat thyroid cells transformed
with oncogenes. V-mos and v-ras-Ki oncogenes were implied to
induce the synthesis of HMGI protein, and the block of this
induction by the presence of an HMGI-C antisense construct could
be shown to inhibit cell transformation. HMGI-C did not behave
like a classical transforming oncogene though, since when trans-
fected in normal thyroid cells, it did not cause their transformation,
thus suggesting that its expression is necessary but not sufficient to
achieve the transformed phenotype (Berlingieri et al, 1995).
Neoplastic transformation was associated with a drastic increase
in AP-1 activity, which was blocked by the suppression of HMGI
protein synthesis. The absence of AP-1 transcriptional activity
induction, directly or indirectly regulated by the HMGI proteins,
would inhibit the expression of AP-1-dependent genes such as
VEGF, collagenase I and stromelysin, which are required for
neoplastic cell transformation (Vallone et al, 1997). It was noted
that the high intracellular levels of HMGI proteins in transformed
malignant cells are not simply the result of increased cellular
proliferation. In fact, nontransformed cells proliferating at
approximately the same rate as their transformed counterpart
expressed consistently lower HMGI-C or HMGI(Y) (Tallini and Dal
Cin, 1999). A recent study by Scala et al (2001) showed though,
that in pygmy mice carrying a disrupted HMGI-C gene, induction
of thyroid carcinomas with radiation or the E7 papilloma virus
oncogene took place with the same frequency as in wildtype mice,
therefore indicating that HMGI-C is not necessarily required for in
vivo thyroid carcinogenesis (Scala et al, 2001). It was considered
that HMGI(Y) proteins, rather than HMGI-C, may be required for
thyroid cell transformation.
Similar observations as for HMGI-C concerning its expression in
association with grade and stage of tumours were made for
HMGI(Y), given its 50% amino-acid sequence homology with
HMGI-C (Tallini and Dal Cin, 1999). In a study on colorectal
neoplastic tissues a correlation could be found between an
increased HMGI(Y) protein expression because of an increase in
its mRNA and various clinicopathological parameters, known to be
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 HMGI-C negative 
P = 0.0001 
Figure 1 Kaplan–Meier curves for disease-specific survival of 69
metastatic breast cancer patients with detectable HMGI-C expression
(HMGI-C positive, N¼21) vs patients in whom HMGI-C could not be
detected (HMGI-C negative, N¼48) by RT–PCR in peripheral blood.
Table 2 Prognostic significance of HMGI-C mRNA in peripheral blood




Oestrogen receptor status 0.055
Progesterone receptor status 0.49
Menopausal status 0.39
Liver and lung metastases 0.10
Sites of metastases 42 0.16
Adjuvant chemotherapy 0.20
Table 3 Multivariate analysis using the stepwise Cox regression model
for overall survival, final model
Multivariate analysis
Variables Hazard ratio 95% CI P-value
HMGI-C expression 6.38 2.22–18.34 0.001
Oestrogen receptor positivity 0.31 0.11–0.86 0.024
Liver and lung metastases 3.46 1.13–10.58 0.029
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yindicative of a poor prognosis (Abe et al, 1999). A significant
correlation between HMGI(Y) mRNA expression and tumour
grade and stage could be found in another study on prostate
cancer (Tamimi et al, 1996). The above data demonstrate that
HMGI-C and HMGI(Y) are important elements in tumorigenesis,
while a precise definition of their role in tumour initiation and
progression is still missing. So far studies on the expression of
HMGI-C had focused on tumour tissues and cell lines and only one
study was available on HMGI-C expression in the peripheral blood
of leukemia patients, until we could recently demonstrate that
HMGI-C is expressed in the peripheral blood of a subset of patients
with breast cancer. This expression was restricted to patients with
metastatic disease.
In the present study, we evaluated the prognostic relevance of
HMGI-C expression in the peripheral blood of breast cancer
patients with metastatic disease with respect to clinicopathologic
parameters. We could show for the first time that HMGI-C
expression is highly significant for worse outcome in univariate
analysis, and we could furthermore demonstrate in multivariate
analysis that circulating HMGI-C mRNA is a powerful independent
prognostic indicator for overall survival. The significance of
HMGI-C mRNA detection in peripheral blood, even allowing for
the relatively small number of patients with metastatic breast
cancer studied here, implies that this is a particularly strong
prognostic factor. The multivariate analysis also showed that the
presence of lung and liver metastases was significantly associated
with worse outcome, which is consistent with previous studies, as
is the fact that patients who were oestrogen receptor positive had
significantly better overall survival (Rizzieri et al, 1999).
Reverse transcription–polymerase chain reaction of peripheral
blood for HMGI-C mRNA, identifying those patients with
metastatic breast cancer with an unfavourable prognosis, could
be of diagnostic importance complementary to current methods
for assessment of disease status and prediction of outcome,
reflecting distinct biologic features of the disease. So far no
expression of HMGI-C in the peripheral blood of healthy controls
could be found, which is of advantage, since the specificity of other
RT–PCR assays in breast cancer, such as RT–PCR for cytokeratin
19, had to be questioned due to an expression in healthy controls
(Bostick et al, 1998; Slade et al, 1999).
The additional information gained by RT–PCR for HMGI-C
may help to improve treatment strategies in allowing for a
selection of breast cancer patients with metastatic disease with a
worse prognosis. Further studies are needed to evaluate tailored
therapy options for this risk group of patients with a particularly
poor prognosis.
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